Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gideon Bollag

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
The Journal of Clinical Investigation|November 23, 2011
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationDebyani Chakravarty, Elmer Santos, Mabel Ryder, et al.
Nature Communications|November 17, 2025
RAF inhibitors activate the integrated stress response by direct activation of GCN2Rebecca Gilley, Andrew M Kidger, Graham Neill, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerLuping Lin, Saurabh Asthana, Elton Chan, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Cell Reports|February 9, 2016
KRAS Engages AGO2 to Enhance Cellular TransformationSunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, et al.
Structure (London, England : 1993)|December 4, 2004
Structural basis for the activity of drugs that inhibit phosphodiesterasesGraeme L Card, Bruce P England, Yoshihisa Suzuki, et al.
Cancer Research|March 5, 2015
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapyJemima Escamilla, Shiruyeh Schokrpur, Connie Liu, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Frontiers in Oncology|November 1, 2021
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-<i>Versus</i>-Host DiseaseKatiri J Snyder, Hannah K Choe, Yandi Gao, et al.
Nature Genetics|February 14, 2006
Germline KRAS mutations cause Noonan syndromeSuzanne Schubbert, Martin Zenker, Sara L Rowe, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
The Journal of Clinical Investigation|November 23, 2011
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activationDebyani Chakravarty, Elmer Santos, Mabel Ryder, et al.
Nature Communications|November 17, 2025
RAF inhibitors activate the integrated stress response by direct activation of GCN2Rebecca Gilley, Andrew M Kidger, Graham Neill, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 20, 2014
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerLuping Lin, Saurabh Asthana, Elton Chan, et al.
Nature Communications|November 5, 2025
Targeting TAZ-TEAD in minimal residual disease enhances the duration of targeted therapy in melanoma modelsConnor A Ott, Timothy J Purwin, Pan-Yu Chen, et al.
Cell Reports|February 9, 2016
KRAS Engages AGO2 to Enhance Cellular TransformationSunita Shankar, Sethuramasundaram Pitchiaya, Rohit Malik, et al.
Structure (London, England : 1993)|December 4, 2004
Structural basis for the activity of drugs that inhibit phosphodiesterasesGraeme L Card, Bruce P England, Yoshihisa Suzuki, et al.
Cancer Research|March 5, 2015
CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapyJemima Escamilla, Shiruyeh Schokrpur, Connie Liu, et al.
Blood Advances|April 25, 2020
A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemiaCatherine C Smith, Mark J Levis, Olga Frankfurt, et al.
Frontiers in Oncology|November 1, 2021
Inhibition of Bromodomain and Extra Terminal (BET) Domain Activity Modulates the IL-23R/IL-17 Axis and Suppresses Acute Graft-<i>Versus</i>-Host DiseaseKatiri J Snyder, Hannah K Choe, Yandi Gao, et al.
Nature Genetics|February 14, 2006
Germline KRAS mutations cause Noonan syndromeSuzanne Schubbert, Martin Zenker, Sara L Rowe, et al.
Pageof 9